Galimedix, Inc. | WebDisclosure

Basculer en Français

10169	Companies
209109	Keywords
139213	Articles
110847	Press releases

Home
Companies
Galimedix, Inc.

PRESS RELEASE

published on 05/06/2025 at 14:00, 11 months 1 day ago

Galimedix Therapeutics completes single ascending dose part of Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modulator
Galimedix Therapeutics completes single ascending dose of Phase 1 study with oral small molecule GAL-101 targeting amyloid beta aggregation modulator, supporting oral administration route. Next study arms and indications revealed

Galimedix Therapeutics GAL-101 Oral Administration Phase 1 Study Amyloid Beta
BRIEF

published on 04/01/2025 at 09:05, 1 year ago

Galimedix Reports Promising Data for Alzheimer's Treatment

Alzheimer's Disease GAL-201 Galimedix Therapeutics Neuroinflammation Amyloid-β Aggregation
BRIEF

published on 04/01/2025 at 09:05, 1 year ago

Galimedix publie des données prometteuses pour le traitement de la maladie d'Alzheimer

GAL-201 Maladie D'Alzheimer Galimedix Therapeutics Neuroinflammation Agrégation De L'amyloïde-β
PRESS RELEASE

published on 04/01/2025 at 09:00, 1 year ago

Galimedix Therapeutics presents further scientific data showing disease-modifying potential of oral GAL-201 in Alzheimer’s disease as well as beneficial effects on synaptic function and neuroimmunomod
Galimedix Therapeutics presents new preclinical data on GAL-201 at AD/PD 2025, showing promise in Alzheimer’s disease treatment by targeting misfolded Aβ monomers and reducing Aβ plaques with anti-inflammatory effects

Alzheimer's Disease Preclinical Data GAL-201 Galimedix Therapeutics Neuroinflammation
BRIEF

published on 03/24/2025 at 15:12, 1 year ago

Galimedix Therapeutics présente un traitement préclinique prometteur contre la maladie d'Alzheimer

Galimedix Therapeutics Neuroprotection Données Précliniques Traitement De La Maladie D'Alzheimer Bêta-amyloïde
BRIEF

published on 03/24/2025 at 15:12, 1 year ago

Galimedix Therapeutics to Present Promising Preclinical Alzheimer’s Treatment

Preclinical Data Galimedix Therapeutics Neuroprotection Alzheimer's Treatment Amyloid-beta
PRESS RELEASE

published on 03/24/2025 at 15:07, 1 year ago

Galimedix Therapeutics to present positive pre-clinical data with amyloid beta aggregation modulator in development for oral Alzheimer’s disease treatment at AD/PD™ 2025 Conference
Galimedix Therapeutics to present positive pre-clinical data with amyloid beta aggregation modulator for oral Alzheimer's disease treatment at AD/PD(TM) 2025 Conference

Alzheimer's Disease Galimedix Therapeutics Pre-clinical Data AD/PD 2025 Conference Aβ Aggregation Modulator
BRIEF

published on 12/23/2024 at 17:35, 1 year 3 months ago

Galimedix débute un essai de phase 2 avec les gouttes ophtalmiques GAL-101 pour la DMLA sèche

Étude De Phase 2 Neuroprotection GAL-101 DMLA Sèche Atrophie Géographique
BRIEF

published on 12/23/2024 at 17:35, 1 year 3 months ago

Galimedix Begins Phase 2 Trial with GAL-101 Eye Drops for Dry AMD

Phase 2 Study Neuroprotection GAL-101 Dry AMD Geographic Atrophy
PRESS RELEASE

published on 12/23/2024 at 17:30, 1 year 3 months ago

Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD
Galimedix Therapeutics initiates Phase 2 study with GAL-101 eye drops for dry AMD, aiming to slow geographic atrophy growth. Trial led by world-leading retina experts and funded by Théa Open Innovation

Galimedix Therapeutics Phase 2 Study GAL-101 Dry AMD Geographic Atrophy

Accesswire

Published on 04/08/2026 at 08:05, 1 hour 32 minutes ago

Tocvan Announces Addition of Second Drill Rig and Accelerates High-Priority Drill Targets at Flagship Gran Pilar Gold-Silver Project
Published on 04/08/2026 at 02:50, 6 hours 47 minutes ago

Panther Minerals Announces Appointment of Rick Mah to Board of Directors
Published on 04/08/2026 at 01:35, 8 hours 2 minutes ago

Polaris Renewable Energy Announces Q1 2026 Investor Call Details
Published on 04/08/2026 at 00:40, 8 hours 57 minutes ago

Relevant Gold Announces Initial Closing of Strategic Financing
Published on 04/08/2026 at 00:10, 9 hours 27 minutes ago

Trans Canada Gold Completes the Acquisition of the Harrison Lake District Scale Gold Property and First Tranche of the Non-Brokered Private Placement

View all ACCESSWIRE

EQS Group

Published on 04/08/2026 at 09:23, 13 minutes ago

IBU-tec advanced materials AG: 2025 annual financial statements presented and dividend proposal of EUR 0.12 per share
Published on 04/08/2026 at 09:10, 27 minutes ago

Reolink Announces Official Integration with Homey to Elevate Smart Home Automation
Published on 04/08/2026 at 09:05, 32 minutes ago

Lenzing Commissions 14 MW Power‑to‑Heat Facility, Strengthening Grid Stability and Heat Management
Published on 04/08/2026 at 09:00, 36 minutes ago

Original-Research: EPH Group AG (von NuWays AG): BUY
Published on 04/08/2026 at 09:00, 36 minutes ago

Original-Research: ASMALLWORLD AG (von NuWays AG): BUY

Les Echos

Published on 04/08/2026 at 08:30, 1 hour 7 minutes ago

Edenred Mobility and Electra form a strategic partnership to accelerate the electrification of commercial fleets in France
Published on 04/08/2026 at 08:30, 1 hour 7 minutes ago

Edenred Mobilité et Electra nouent un partenariat stratégique pour accélérer l’électrification des flottes professionnelles en France
Published on 04/07/2026 at 18:00, 15 hours 37 minutes ago

LDC : Chiffre d’affaires du 4 ème trimestre 2025-2026. Solide croissance du chiffre d’affaires au 4ème trimestre 2025-2026 et révision à la hausse des objectifs.
Published on 04/07/2026 at 17:57, 15 hours 40 minutes ago

Peugeot Invest publishes its 2025 Universal Registration Document
Published on 04/07/2026 at 17:57, 15 hours 40 minutes ago

Mise à disposition du Document d’enregistrement universel 2025

View all LES ECHOS COMFI WIRE